Table 2. ORR in the overall population, and in patient subgroups based on baseline brain metastases, dose modifications, and location of baseline EGFR mutation(s).
| Best overall response, n (%) | All evaluable patients (n=366) | Baseline brain metastases | Dose modification | EGFR mutation locationa | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes (n=148) | No (n=214) | Yes (n=233) | No (n=133) | Exon 18 (n=19) | Exon 19 (n=225) | Exon 20 (n=15) | Exon 21 (n=118) | Unknown (n=3) | ||||
| CR | 6 (1.6) | 1 (0.7) | 4 (1.9) | 4 (1.7) | 2 (1.5) | 1 (5.3) | 4 (1.8) | 1 (6.7) | 1 (0.8) | 0 (0) | ||
| PR | 223 (60.9) | 102 (68.9) | 120 (56.1) | 149 (63.9) | 74 (55.6) | 9 (47.4) | 140 (62.2) | 3 (20.0) | 73 (61.9) | 2 (66.7) | ||
| SD | 107 (29.2) | 29 (19.6) | 76 (35.5) | 64 (27.5) | 43 (32.3) | 7 (36.8) | 66 (29.3) | 8 (53.3) | 34 (28.8) | 0 (0) | ||
| PD | 30 (8.2) | 16 (10.8) | 14 (6.5) | 16 (6.9) | 14 (10.5) | 2 (10.5) | 15 (6.7) | 3 (20.0) | 10 (8.5) | 1 (33.3) | ||
| ORR | 229 (62.6) | 103 (69.6) | 124 (57.9) | 153 (65.7) | 76 (57.1) | 10 (52.6) | 144 (64.0) | 4 (26.7) | 74 (62.7) | 2 (66.7) | ||
| DCR | 336 (91.8) | 132 (89.2) | 200 (93.5) | 217 (93.1) | 119 (89.5) | 17 (89.5) | 210 (93.3) | 12 (80.0) | 108 (91.5) | 2 (66.7) | ||
a, patients may appear in >1 category; specific mutations include: G719X (exon 18), Del19 (exon 19), S7681 (exon 20), L858R and L861Q (exon 21). ORR, overall response rate; EGFR, epidermal growth factor receptor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate.